Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Cancer Research

• Publication date

  2011-08-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-11-1463PMID 21880788PMCID PMC3196047
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020cited by this paper
• BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

  2012cited by this paper
• Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

  2010cited by this paper
• Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

  2010cited by this paper
• First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07).

  2010cited by this paper
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

  2010cited by this paper
• Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome

  2010cited by this paper
• Predictors of competing mortality in advanced head and neck cancer.

  2010cited by this paper
• Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.

  2009cited by this paper
• 23LBA BEAM: A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma

  2009cited by this paper
• Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma

  2009cited by this paper
• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.

  2009cited by this paper
• Management of hypertension in angiogenesis inhibitor-treated patients.

  2009cited by this paper
• Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.

  2009influential reference
• Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

  2008cited by this paper
• Reactive oxygen species: an Achilles’ heel of melanoma?

  2008cited by this paper
• Tumor angiogenesis.

  2008cited by this paper
• Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

  2008cited by this paper
• Angiogenesis in melanoma.

  2007cited by this paper
• VEGF, VEGFR1, and VEGFR2 expression in melanoma

  2007cited by this paper
• Mechanisms of hypertension associated with BAY 43-9006.

  2006cited by this paper
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  2006cited by this paper
• Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis

  2006cited by this paper
• Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series.

  2006cited by this paper
• Soluble VEGF-A and lymphangiogenesis in metastatic malignant melanoma patients.

  2006cited by this paper
• Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients

  2006cited by this paper
• Relationship of soluble VEGF-C and VEGF-D with clinicopathological parameters in metastatic malignant melanoma patients treated by biochemotherapy

  2005cited by this paper
• Therapeutic angiogenesis and vasculogenesis for tissue regeneration

  2005cited by this paper
• Manipulating angiogenesis in medicine

  2004cited by this paper
• Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Changes in circulating VEGF-A levels related to clinical response during biochemotherapy in metastatic malignant melanoma.

  2004cited by this paper
• Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy

  2003cited by this paper
• VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

  2003cited by this paper
• The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis

  2003cited by this paper
• Clinical trial designs for cytostatic agents: are new approaches needed?

  2001cited by this paper
• Clinical implications of circulating angiogenic factors in cancer patients.

  2001influential reference
• Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

  2000cited by this paper
• VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.

  1998cited by this paper
• VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.

  1998cited by this paper
• Vascular endothelial growth factor expression in early stage ovarian carcinoma

  1997influential reference
• Errata

  1996cited by this paper
• Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

  1996cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971influential reference

• Current Therapies and Potential Strategies for Uveal Melanoma.

  2025influential citation
• Melanoma-derived extracellular vesicles transfer proangiogenic factors

  2025cites this paper
• HDAC/σ1R Dual-Ligand as a Targeted Melanoma Therapeutic

  2025cites this paper
• VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives.

  2024cites this paper
• Biological characteristics and clinical management of uveal and conjunctival melanoma

  2024cites this paper
• Updates in the Management of Uveal Melanoma.

  2024cites this paper
• Order of patient entry and outcomes in phase II clinical trials: A meta-analysis of individual patient data.

  2023cites this paper
• Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis

  2023cites this paper
• Advances in targeted therapy and immunotherapy for melanoma (Review)

  2023cites this paper
• Advances in the clinical management of uveal melanoma

  2023cites this paper
• Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

  2022cites this paper
• Inhibition of CD146 lessens uveal melanoma progression through reducing angiogenesis and vasculogenic mimicry

  2022cites this paper
• Antiangiogenic drugs as chemosensitizer in melanoma

  2022cites this paper
• Haloperidol Metabolite II Valproate Ester (S)-(−)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma

  2021cites this paper
• New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review

  2021cites this paper
• Development of new therapeutic options for the treatment of uveal melanoma

  2021cites this paper
• In vitro and in ovo experimental study of two anti-VEGF agents used in ophthalmology

  2021cites this paper
• Hypoxia-dependent drivers of melanoma progression

  2021cites this paper
• Neoangiogenesis in Melanoma: An Issue in Biology and Systemic Treatment

  2020cites this paper
• Nucleic Acid-Based Approaches for Tumor Therapy

  2020cites this paper
• Targeting Epigenetic Modifications in Uveal Melanoma

  2020cites this paper
• Systemic Therapy for Mucosal, Acral, and Uveal Melanoma

  2020cites this paper
• Correlation between the Expression of Angiogenic Factors and Stem Cell Markers in Human Uveal Melanoma

  2020cites this paper
• Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma

  2020cites this paper
• Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?

  2019cites this paper
• Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers

  2019cites this paper
• Cancer Angiogenesis

  2019cites this paper
• Uveal Melanoma: an Updated Review

  2019cites this paper
• Uveal Melanoma: Adjuvant Therapy

  2019cites this paper
• Systemic Therapy for Mucosal, Acral and Uveal Melanoma

  2019cites this paper
• Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives

  2019cites this paper
• Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study.

  2019cites this paper
• Targeting tyrosine kinases for treatment of ocular tumors

  2018cites this paper
• Oncogenic signaling in uveal melanoma

  2018cites this paper
• NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma

  2018cites this paper
• R

  2018cites this paper
• Uveale Melanomzellen unter oxidativem Stress – Einfluss von VEGF und VEGF-Inhibitoren

  2017cites this paper
• Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions.

  2017cites this paper
• Targeting Melanoma with Cancer-Killing Viruses

  2017cites this paper
• Implications of MEK and VEGFR2 inhibition on melanoma CXCR4-CXCL12 chemotaxis, survival and tumour progression

  2017cites this paper
• Update on Metastatic Uveal Melanoma: Progress and Challenges

  2016cites this paper
• Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis

  2016cites this paper
• Uveal melanoma: From diagnosis to treatment and the science in between

  2016cites this paper
• Intractable leg ulcers in Blau syndrome

  2016cites this paper
• Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

  2016cites this paper
• Stereotactic radiotherapy of uveal melanoma: The Dunedin Experience

  2016cites this paper
• Ulcerations on abdominal wound scar associated with aflibercept therapy

  2016cites this paper
• Dynamics of VEGF-A and its Receptors in Cancer Vascularization – an Overview

  2016cites this paper
• Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma

  2015cites this paper
• Aflibercept a new target therapy in cancer treatment: a review.

  2015cites this paper
• Cancer prevention and therapy through the modulation of the tumor microenvironment.

  2015cites this paper
• ancer prevention and therapy through the modulation of the tumor icroenvironment

  2015cites this paper
• Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data

  2015cites this paper
• Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis

  2014cites this paper
• Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis

  2014cites this paper
• Biology of advanced uveal melanoma and next steps for clinical therapeutics

  2014cites this paper
• Intra‐arterial infusion and chemo‐embolization for melanoma liver metastases

  2014cites this paper
• BRAF and beyond: Tailoring strategies for the individual melanoma patient

  2014cites this paper
• A Review of Novel Therapies for Melanoma

  2014cites this paper
• Incidence and Risk of Proteinuria with Aflibercept in Cancer Patients: A Meta-Analysis

  2014cites this paper
• Oncogene withdrawal engages the immune system to induce sustained cancer regression

  2014cites this paper
• Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma – implications for therapeutic strategies and targeted therapies

  2014cites this paper
• Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.

  2014cites this paper
• Clinical activity of ipilimumab for metastatic uveal melanoma

  2013cites this paper
• Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis

  2013cites this paper
• Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia

  2013cites this paper
• New Developments in the Second-Line Treatment of Metastatic Colorectal Cancer: Potential Place in Therapy

  2013cites this paper
• Intravitreal aflibercept for neovascular age-related macular degeneration.

  2013cites this paper
• Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.

  2013cites this paper
• Biomarkers for Anti-Angiogenic Therapy in Cancer

  2013cites this paper
• Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy.

  2013cites this paper
• Inhibition of Angiogenesis for the Treatment of Metastatic Melanoma

  2013cites this paper
• Cancer Chemotherapy Update Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome

  2013cites this paper
• Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome

  2013cites this paper
• Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch

  2013cites this paper
• Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives

  2013cites this paper
• Multidisciplinary approach to patient with malignant melanoma.

  2013cites this paper
• Extending foldamer design beyond α-helix mimicry: α/β-peptide inhibitors of vascular endothelial growth factor signaling.

  2012cites this paper
• Combinatorial treatment with carboxyamidotriazole- orotate and temozolomide in sc-implanted human LOX IMVI melanoma xenografts

  2012cites this paper
• Melanoma: new insights and new therapies.

  2012cites this paper
• Ocular melanoma: what's new?

  2012cites this paper
• Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib

  2012cites this paper
• Antibody-based therapeutics to watch in 2011

  2011cites this paper
• Novel Antibody-Based Proteins for Cancer Immunotherapy

  2011cites this paper
• Targeting angiogenesis in melanoma: prospects for the future

  2010cites this paper
• Clinical, Cosmetic and Investigational Dermatology Vascular Endothelial Growth Factor Inhibitors: Investigational Therapies for the Treatment of Psoriasis

  year unknowncites this paper